Get the Stockscreener App
25.30
0.59%
-0.15
After Hours:
25.30
Quidelortho Corporation stock is traded at $25.30, with a volume of 1.75M.
It is down -0.59% in the last 24 hours and down -9.74% over the past month.
QuidelOrtho Corp is engaged in the development, manufacturing and marketing of rapid diagnostic testing solutions. The company is engaged in immunoassay and molecular testing, clinical chemistry and transfusion medicine which helps clinicians and patients to make decisions across the globe. Geographically the company has its presence in North America, EMEA, China and Other countries. It generates majority if its revenue from North America.
See More
Previous Close:
$25.45
Open:
$25.55
24h Volume:
1.75M
Relative Volume:
1.10
Market Cap:
$1.71B
Revenue:
$2.76B
Net Income/Loss:
$-358.70M
P/E Ratio:
-5.0905
EPS:
-4.97
Net Cash Flow:
$-35.90M
1W Performance:
-12.34%
1M Performance:
-9.74%
6M Performance:
-42.13%
1Y Performance:
-27.07%
1-Day Range:
$25.25
$26.07
1-Week Range:
$25.25
$29.36
52-Week Range:
$23.77
$49.45
Quidelortho Corporation Stock (QDEL) Company Profile
Name
Quidelortho Corporation
Sector
Industry
Phone
(858) 552-1100
Address
9975 SUMMERS RIDGE ROAD, SAN DIEGO, CA
Compare QDEL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
QDEL
Quidelortho Corporation
|
25.30 | 1.95B | 2.76B | -358.70M | -35.90M | -4.97 |
|
ABT
Abbott Laboratories
|
124.42 | 229.71B | 43.11B | 13.98B | 6.66B | 7.98 |
|
BSX
Boston Scientific Corp
|
103.78 | 154.35B | 17.55B | 2.03B | 2.72B | 1.37 |
|
SYK
Stryker Corp
|
387.32 | 149.60B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
89.70 | 114.97B | 33.54B | 4.66B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
76.56 | 45.92B | 5.54B | 4.18B | 623.10M | 7.00 |
Quidelortho Corporation Stock (QDEL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-08-25 | Upgrade | Jefferies | Hold → Buy |
| Dec-11-24 | Upgrade | Citigroup | Neutral → Buy |
| Dec-10-24 | Initiated | Jefferies | Hold |
| Sep-19-24 | Resumed | UBS | Neutral |
| Sep-05-24 | Upgrade | Craig Hallum | Hold → Buy |
| Mar-04-24 | Downgrade | UBS | Neutral → Sell |
| Feb-14-24 | Downgrade | JP Morgan | Neutral → Underweight |
| Dec-11-23 | Downgrade | Citigroup | Buy → Neutral |
| Dec-12-22 | Upgrade | Citigroup | Neutral → Buy |
| Dec-07-22 | Initiated | RBC Capital Mkts | Outperform |
| Oct-14-22 | Upgrade | UBS | Sell → Neutral |
| Sep-19-22 | Initiated | Citigroup | Neutral |
| Jul-20-22 | Initiated | UBS | Sell |
| Jun-17-22 | Resumed | JP Morgan | Neutral |
| Feb-22-22 | Upgrade | Raymond James | Outperform → Strong Buy |
| Jan-22-21 | Upgrade | Raymond James | Mkt Perform → Outperform |
| May-12-20 | Downgrade | JP Morgan | Neutral → Underweight |
| Mar-26-20 | Downgrade | Barclays | Overweight → Equal Weight |
| Oct-23-18 | Resumed | Raymond James | Strong Buy |
| Mar-08-18 | Upgrade | Raymond James | Outperform → Strong Buy |
| Jan-22-18 | Reiterated | Barclays | Overweight |
| Jan-04-18 | Upgrade | CL King | Neutral → Buy |
| Sep-19-17 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Jul-18-17 | Upgrade | Canaccord Genuity | Hold → Buy |
| Jul-18-17 | Upgrade | William Blair | Mkt Perform → Outperform |
| Apr-25-17 | Reiterated | Canaccord Genuity | Hold |
| Feb-17-17 | Initiated | CL King | Neutral |
| Dec-16-16 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Jun-13-16 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Feb-18-16 | Reiterated | Barclays | Overweight |
| Feb-09-16 | Downgrade | Canaccord Genuity | Buy → Hold |
| Jan-08-16 | Reiterated | Canaccord Genuity | Buy |
| Dec-14-15 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Sep-02-15 | Initiated | Barclays | Overweight |
| Jul-31-13 | Reiterated | Canaccord Genuity | Buy |
| Mar-03-11 | Downgrade | Wedbush | Outperform → Neutral |
View All
Quidelortho Corporation Stock (QDEL) Latest News
What drives QuidelOrtho Corporation stock priceExtraordinary performance - Autocar Professional
Is QuidelOrtho Corporation a good long term investmentOutstanding stock performance - Autocar Professional
QuidelOrtho Corporation Stock Analysis and ForecastHigh-impact stock picks - Autocar Professional
What analysts say about QuidelOrtho Corporation stockDynamic investment opportunities - Autocar Professional
RBC Capital Maintains a Buy Rating on QuidelOrtho Corporation (QDEL), Sets a $60 PT - MSN
QuidelOrtho, Acadia Healthcare, Elevance Health, Molina Healthcare, and Alignment Healthcare Stocks Trade Down, What You Need To Know - MSN
Real Labs, Actual Decisions With Actionable Six Sigma Metrics - The Malaysian Reserve
QuidelOrtho Announces Featured ADLM Session on Six Sigma Insights for Lab Performance - AInvest
QuidelOrtho to present at ADLM on Six Sigma lab performance improvement. - AInvest
Six Sigma Lab Excellence: Top Medical Experts Share Game-Changing Performance Metrics at ADLM Conference - Stock Titan
10 Undervalued Medical Device Stocks to Buy Now - Insider Monkey
Investors in QuidelOrtho (NASDAQ:QDEL) from five years ago are still down 88%, even after 3.8% gain this past week - simplywall.st
QuidelOrtho Corporation and Buildman Laboratories AG Announces Availability of the BuHLMANN FCAL Turbidimetric Immunoassays on Vitroal Pancreatic Elastase - MarketScreener
QuidelOrtho and Bühmann Laboratories AG announce availability of Fecal Calprotectin (Fcal®) Turbo and Fecal Pancreatic Elastase (Fpela®) Turbo assays on Vitros systems as a Microtip partnership assay (Mpa) - MarketScreener
QuidelOrtho's New 10-Minute Diagnostic Tests Transform IBD and Pancreatic Disease Detection - Stock Titan
Acadia Healthcare, 10x Genomics, Amphastar Pharmaceuticals, Myriad Genetics, and QuidelOrtho Stocks Trade Down, What You Need To Know - MSN
A Look Back at Medical Devices & SuppliesImaging, Diagnostics Stocks’ Q1 Earnings: QuidelOrtho (NASDAQ:QDEL) Vs The Rest Of The Pack | FinancialContent - FinancialContent
Nephron Initiates QuidelOrtho(QDEL.US) With Hold Rating, Announces Target Price $40 - 富途牛牛
Best Value Stocks to Buy for July 8th - The Globe and Mail
QuidelOrtho announces key leadership changes - Medical Buyer
QuidelOrtho Strengthens Leadership Team With Appointments of Senior Vice Presidents for Global Quality and Clinical & Regulatory Affairs | QDEL Stock News - GuruFocus
Press Release: QuidelOrtho Strengthens Leadership Team With Appointments of Senior Vice Presidents for Global Quality and Clinical & Regulatory Affairs - 富途牛牛
5 Revealing Analyst Questions From QuidelOrtho’s Q1 Earnings Call - Yahoo Finance
Here's Why QuidelOrtho (QDEL) is a Strong Growth Stock - Nasdaq
RBC Capital Keeps Their Buy Rating on QuidelOrtho (QDEL) - The Globe and Mail
QuidelOrtho's Russell 1000 Exit: Opportunity in the Shadows of Index Exclusion - AInvest
QuidelOrtho Corporation(NasdaqGS: QDEL) added to Russell 3000 Growth Index - MarketScreener
Reasons to Retain QuidelOrtho Stock in Your Portfolio for Now - Yahoo Finance
QuidelOrtho Nabs LEX in $100M M&A - San Diego Business Journal
What Makes QuidelOrtho (QDEL) a New Buy Stock - Nasdaq
Why QuidelOrtho (QDEL) is a Top Growth Stock for the Long-Term - Yahoo Finance
Should Value Investors Buy QuidelOrtho (QDEL) Stock? - Yahoo Finance
This QuidelOrtho Insider Increased Their Holding In The Last Year - simplywall.st
QuidelOrtho Declares that its Molecular Diagnostics Approach will be Refocused - MSN
Lex seeks FDA clearance ahead of $100M Quidelortho takeover - BioWorld MedTech
QuidelOrtho set to buy LEX Diagnostics for $100m after FDA approval trigger - Cambridge Independent
QuidelOrtho Corp (QDEL) Trading 4% Higher on Jun 9 - GuruFocus
QuidelOrtho seeks FDA approval to complete acquisition of LEX Diagnostics - Mugglehead Magazine
QuidelOrtho (QDEL) Down 18% Since Last Earnings Report: Can It Rebound? - Yahoo Finance
Clinical Laboratory Molecular Diagnostics for Infectious Disease Market Research 2025-2029: Biotechnology and Genomics Drive Advancements, Impact of Multiplex Assays in Diagnosis and Treatment - GlobeNewswire Inc.
Quidel at Jefferies Conference: Strategic Shift and Growth Plans - Investing.com
Transcript : QuidelOrtho Corporation Presents at Jefferies Global Healthcare Conference 2025, Jun-05-2025 08 - MarketScreener
Quidelortho Corporation Stock (QDEL) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.15%
0.17%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):